Experimental CAR T-Cell combo aims to stop lymphoma relapse after transplant
NCT ID NCT05432635
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether giving special immune cells (CMV-specific CD19-CAR T cells) along with a vaccine (CMV-MVA triplex) after a stem cell transplant can safely help prevent B-cell non-Hodgkin lymphoma from returning. About 15 people with intermediate or high-grade lymphoma will take part. The main goal is to check for side effects and see if the treatment is feasible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CMV-specific CD19-CAR T cells and CMV-MVA triplex vaccine
- What this could lead to
- If this works, it could point toward a new way to prevent non-Hodgkin lymphoma from coming back after a stem cell transplant.
- What could go wrong
- This is a very early, small phase 1 trial with only 15 people, so it is mainly checking safety. It may not work as hoped, and there could be side effects from the CAR T cells or vaccine.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- A smarter steroid schedule might tame Chemotherapy's blood sugar spike